J&J settles Amgen clash over blockbuster psoriasis drug

25-05-2023

Liz Hockley

J&J settles Amgen clash over blockbuster psoriasis drug

Michael Vi / Shutterstock.com

Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.


Johnson & Johnson, Amgen, Stelara, psoriasis, biosimilar, ulcerative colitis, immunosuppressant, biologic

LSIPR